Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions
Pacelli, A.; Greenman, J.; Cawthorne, C.; Smith, G.
Professor John Greenman J.Greenman@hull.ac.uk
Professor of Tumour Immunology
The role of cyclooxygenase (COX)-2 as a driving force in early tumourigenesis and the current interest in the combination of COX-2 inhibitors with standard therapy in clinical trials creates an urgent need to establish clinically relevant diagnostic tests for COX-2 expression. Molecular imaging using small-molecule probes radiolabelled for both positron emission tomography (PET) and single photon emission computed tomography (SPECT) offers the potential to meet this need, providing a minimally invasive readout for the whole disease burden. This review summarises current approaches to the radiolabelling of small-molecule COX-2 inhibitors and their analogues for PET and SPECT imaging, and gives an overview of their biological evaluation and likely success of clinical application. © 2013 John Wiley & Sons, Ltd.
|Journal Article Type||Article|
|Journal||Journal of labelled compounds and radiopharmaceuticals|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Pacelli, A., Greenman, J., Cawthorne, C., & Smith, G. (2014). Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions. Journal of Labelled Compounds and Radiopharmaceuticals, 57(4), 317-322. doi:10.1002/jlcr.3160|
|Keywords||Coxib; Indole; Imidazole; [11C]-methylation; PET; SPECT; COX-2; Prostaglandin; Cancer; Imaging biomarker|
|Additional Information||This is the author's accepted manuscript of an article published in Journal of labelled compounds and radiopharmaceuticals, 2014, v.57 issue 4.|
You might also like
WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer